EMA To Sit In On French FAAH Inhibitor Inquiry Meeting
This article was originally published in Scrip
Executive Summary
A senior official of the European Medicines Agency is to be an observer on the new French committee set up to look at the preclinical and clinical characteristics of FAAH inhibitors following the death of one volunteer and the hospitalization of several others during a Phase I study of Bial's BIA 10-2474.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.